IFNA1 and psoriasis: If the correlation between high IL-17A levels and poor response to IFN-α treatment is confirmed by large-scale clinical studies, the use of IL-17A neutralizing antibodies (eg. Cosentyx/Secukinumab, a monoclonal antibody that has been approved for the treatment of moderate to severe psoriasis) could be considered in CHB patients with both high IL-17A level and poor IFN-α response.